Jodie Morrison, chief executive officer and director of Q32 Bio Inc., brings two decades of biopharmaceutical leadership experience across private and public biotechnology and pharmaceutical companies from start-up to commercial stage. Jodie was previously chief executive officer of Cadent Therapeutics until its sale to Novartis in 2021. She also served as interim chief executive officer of Keryx Biopharmaceuticals, Inc. (executed its merger of equals with Akebia Therapeutics, Inc. in 2018), acting chief operating officer of Syntimmune, Inc. (acquired by Alexion Pharmaceuticals, Inc.), and president and chief executive officer of Tokai Pharmaceuticals, Inc., where she oversaw the company’s successful initial public offering (IPO) in 2014. Jodie currently serves as an advisor to Atlas Venture, where she previously served as a venture partner, and as a member of the board at Rectify Pharma and of the board of managers at Life Science Cares. 

Jodie holds a B.A. in neuroscience from Mount Holyoke College.